Aurobindo Pharma has decided to replace about 600 products of Actavis with its own low-cost high-margin products to bring down its overall costs. Early this year, the company had acquired the commercial operations of Actavis Plc in seven Western European countries for €30 million. To bring down the overall cost Aurobindo is switching the Actavis product with its own. Out of 450 molecules, 200 are likely to be replaced while in terms of products forms, 600 out of 1,200 could be replaced over the next 24 months, depending on R&D and manufacturing capacity creation in Aurobindo. This replacement would reduce the cost and improve the margins
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
